Hyungsoon Im

Tumors resistant to one ADC can regain sensitivity to another ADC with a different payload. Our work shows payload choice—not just target expression—may extend clinical benefit in breast cancer. No evidence that sequential of FDA approved drugs are beneficial in the clinical setting. pubmed.ncbi.nlm.nih.gov/41591991/

T-DXd resistance mechanisms are complex, heterogenous, context-dependent. In our Spotlight piece just published in @CD_AACR, @tess_omeara and I comment on recent findings, highlighting potentially different paths to resistance in HER2+ and HER2-low MBC. aacrjournals.org/cancerdiscover…

🧬"Hallmarks of cancer" Update Then and now, and beyond 🚀 👉cell.com/action/showPdf… #cancer #oncology #MedX @OncoAlert @1989_mariab @World_Data_A @_atanas_ @Aiims1742

DESTINY-Breast09, PATINA, HER2CLIMB-05… how to put it all together? How to treat HER2+ MBC in 2026? Nice Bridging the Gap piece by @ValenzaCarmine providing a framework for integrating the multiple new frontline option for HER2+ disease. ascopubs.org/doi/10.1200/JC…

🧬🛡️ HER2-low tumors escape HER2 ADCs by losing the target • True HER2 loss is uncommon in HER2-amplified disease but frequent in HER2-low, where HER2 isn’t oncogenic • On HER2 ADC therapy, ~50% of tumors reduce HER2; among reducers, ~half become IHC 0 • Reduced HER2 → impaired ADC internalization, not payload resistance • ERBB2 ECD variants disrupt antibody binding and phenocopy antigen loss • Suggested strategy: multi-target payload delivery to bypass target dependence and improve durability aacrjournals.org/cancerdiscover…

New perspective in @NatureRevCancer Defining precancer: a grand challenge for the cancer community nature.com/articles/s4156… From @theNCI Precancer Think Tank Team, we hope the article provides researchers with a framework to start addressing key topics in preneoplasia research.

What happens to an ADC after its infusion? How does it interact with tumor & immune cells, what causes response & resistance? Take a deep dive in the molecular world of ADCs though our last review, led by @AlfredZippelius and published in @NatureRevCancer. nature.com/articles/s4156…

ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. nature.com/articles/s4159…

🧵 CRP vs Procalcitonin – Inflammation vs Infection? Both rise in systemic illness. But they don’t speak the same language. Let’s break down when to use CRP, when to trust Procalcitonin—and when both lie. 👇 @IhabFathiSulima @DrAkhilX @Janetbirdope @emcrit @andrewsuleh @Lupusreference #MedTwitter

Excellent review in @NatRevClinOncol📣🌟 An integrated algorithm for Cancer of Unknown Primary diagnosis & treatment combines histologic morphology, IHC, gene expression profiling & genomic sequencing, establishing a new therapeutic paradigm. doi.org/10.1038/s41571… @OncoAlert

Multiple ADCs have outperformed chemo for treating mBC. Yet their most transformative impact is expected in the curative setting. DB11 will report at #ESMO25 & much more is coming. We review the field in our latest NPJ Breast review, led by Pooja Patel. nature.com/articles/s4152…

Cancer vaccines will be a big part of the future of immunotherapy. A new, super review @TheLancet thelancet.com/journals/lance…

A new cell line atlas of biliary tract cancers uncovers new subtypes and potential drug targets for better treatment of these deadly diseases. Learn more: broad.io/DepMap-BTCs @MGBResearchNews @targetcancer

The ultimate ADC review! 40 years of ADC. Must read for residents. 10.1158/2159-8290.CD-24-0708 @tuttsakhil @drvineetgovinda @shaunak_3 @SuyogCancer @todrashish @jtgeorgy @ajoyojohn

Happy to share our new review article on the sensing and imaging of #ExtracellularVesicles. Published with @SpringerNature in @LightSciAppl. @MGHCSB @MGBResearchNews nature.com/articles/s4137…

🎯 ADC success rate & time in Phase: ~10% of phase 1 ADCs makes it to approval (three times higher than other drug classes) Recent ADCs took a median time of 7 years from clinical introduction to approval. Shortest time for T-DXd (only 4 years!) Via Lavinia Woodward (#Beacon)

12 lessons students learn in the Sinclair Lab: Lesson 1. Write the way you speak

Online now: Strategies for mitigating data heterogeneities in AI-based neuro-disease detection dlvr.it/TJJC9F

When AI models are developed based on clinical data, many issues with data heterogeneity are often overlooked. In this NeuroView article published in Neuron, we shared our strategies for mitigating these underlying issues in developing neuro-AI models. dlvr.it/TJJC9F

Analyzing a big stack of images from #Microscopy 🔬? Check out our CycloNET pipeline to ease your workload. The paper is officially out 🎉. The code is open for everyone to access on the @MGHCSB site (csb.mgh.harvard.edu/bme_software). doi.org/10.1038/s41598…